← All trials
NCT06558422
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Feb 28, 2027
- First posted
- Aug 16, 2024
- Last posted
- Sep 20, 2024
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of California, BerkeleyCollaborator
- Columbia UniversityOfficial
- Columbia UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.